Paasa Logo
Lyell Immunopharma, Inc. logo
LYELNASDAQMarket closedOpens 9:30am ET

Lyell Immunopharma, Inc.

$9.79Last updated
+$0.16 (1.66%)Past day
Timezone

Lyell Immunopharma, Inc. (NASDAQ: LYEL) is trading at $9.79, about ₹940 at today's USD/INR rate, as of 30 Sep 2026, 4:00 PM ET, up 1.66% today. Indian residents can buy Lyell Immunopharma from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:$10.00
Previous close:$9.63
Volume:153.94K

Today's low

$9.48

Today's high

$10.00

52 week low

$7.65

52 week high

$45.00

LYEL opened at $10.00, closed previously at $9.63, and has traded between $7.65 and $45.00 over the past 52 weeks.

About

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Country
US
CEO
Lynn Seely
Exchange listed on
NASDAQ
Industry
Biotechnology
Base currency
USD
Full Time Employees
161
Sector
Healthcare
IPO date
17/06/2021

Key statistics

Avg. volume

168.64K

Market cap

$239.90M

P/E Ratio

-0.61

Price-to-sales ratio

8885.10

Enterprise value

$516.94M

Free cash flow yield

-28.66%

Debt-to-equity ratio

0.16

Return on equity

-110.57%

ROIC

-67.99%

Beta

-0.07

Dividend yield

0.00%

Last dividend

$0.00

Financial overview

Revenue

$36.00K

Earnings per share

-$16.06

Free cash flow

-$150.80M

Net profit margin

-920285.19%

Gross margin

-8537.04%

EBITDA

-$262.91M

Revenue growth

-40.98%

Similar securities

This is not an investment recommendation

How to buy Lyell Immunopharma from India

Indian residents can buy Lyell Immunopharma shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.

  3. Search for Lyell Immunopharma and place an order

    Find Lyell Immunopharma by name or by its ticker, LYEL, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Lyell Immunopharma trades 7:00 pm – 1:30 am IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Lyell Immunopharma position in USD and INR. Lyell Immunopharma pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in Lyell Immunopharma from India

Trading and taxes when buying Lyell Immunopharma from India

Trading and limits

Trading hours
9:30 am – 4:00 pm ET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneLyell Immunopharma does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
US estate tax
May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator

Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

FAQs

Can Indian residents buy Lyell Immunopharma stock?

Yes. Lyell Immunopharma (LYEL) has been listed on NASDAQ since 2021, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

How much does one Lyell Immunopharma share cost in rupees?

One Lyell Immunopharma share is $9.79 — about ₹940 at a USD/INR rate of 96.06 on 29 Sep 2026. Both the Lyell Immunopharma price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Lyell Immunopharma from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

Can I buy whole shares of Lyell Immunopharma?

Yes. One Lyell Immunopharma share is $9.79, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Lyell Immunopharma.

How are gains on Lyell Immunopharma shares taxed in India?

The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Lyell Immunopharma price. Paasa issues a capital-gains statement for your return.

Does Lyell Immunopharma pay a dividend?

No. Lyell Immunopharma does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade Lyell Immunopharma from India?

NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.

Is there estate or inheritance tax on Lyell Immunopharma shares held from India?

US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.

Do I have to declare Lyell Immunopharma shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Lyell Immunopharma holding, its cost and its closing value.

How do I sell Lyell Immunopharma and bring the money back to India?

You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.